Metabolic Liver Disease: 1.8 Billion People Projected to Be Affected by 2050

A growing global health crisis is unfolding as metabolic liver disease reaches unprecedented levels. Recent data indicates that metabolic dysfunction-associated steatotic liver disease (MASLD)—formerly known as non-alcoholic fatty liver disease (NAFLD)—is one of the fastest-growing liver conditions worldwide. Driven by rising obesity and blood sugar levels, the prevalence of this condition is projected to climb significantly over the next few decades.

Understanding MASLD: What is Metabolic Liver Disease?

Metabolic dysfunction-associated steatotic liver disease (MASLD) occurs in individuals who drink no or minimal amounts of alcohol but have a liver containing more than 5% fat. This condition is closely linked to metabolic dysfunction, which often manifests as obesity or insulin resistance.

In the US and Europe, MASLD has already become the second leading cause of liver transplantation and end-stage liver disease as of 2023, according to reports from the American Journal of Managed Care.

The Alarming Rise in Global Prevalence

The scale of the increase in MASLD cases over the last thirty years is stark. According to a study published in the Lancet Gastroenterology & Hepatology journal and reported by The Guardian, the numbers have surged as follows:

• 1990: Approximately 500 million people lived with MASLD.
• 2023: The number rose to 1.3 billion, representing a 143% increase in three decades.
• 2050 (Projected): The condition is expected to affect 1.8 billion people, a 42% increase from 2023 levels.

The global prevalence rate reached 14,429 cases per 100,000 people in 2023, a 29% increase since 1990.

Who is Most at Risk?

While MASLD affects a broad spectrum of the population, certain demographics indicate higher prevalence rates:

• Gender: The condition is more common in men than in women.
• Age: The highest prevalence rates are found in older adults aged between 80 and 84.
• Peak Impact: Despite higher rates in the elderly, the largest number of affected individuals are younger—specifically men aged 35 to 39 and women aged 55 to 59.

Leading Risk Factors

The rise in MASLD is primarily fueled by global population growth and lifestyle changes. The leading drivers of related health problems include:

1. High blood sugar: The primary driver of MASLD-related complications.
2. High BMI: Obesity is a significant contributing factor.
3. Smoking: Identified as a key driver alongside metabolic markers.

The Danger of Undiagnosed Disease

A critical challenge in managing this epidemic is the lack of awareness. Research indicates that more than 15 million people in the US, UK, Germany, and France are unaware they have MASH—the most aggressive form of fatty liver disease. Because the condition often develops silently, many patients do not seek medical attention until the disease has progressed significantly.

Managing and Preventing MASLD

Addressing the growth of metabolic liver disease requires a combination of systemic public health changes and individual interventions. Dietary patterns play a vital role in the progression of metabolic dysfunction-associated fatty liver disease, and targeted dietary interventions are essential for patient management.

Frequently Asked Questions

What is the difference between NAFLD and MASLD?
MASLD (Metabolic dysfunction-associated steatotic liver disease) is the formal, updated name for what was previously known as non-alcoholic fatty liver disease (NAFLD).

Why is high blood sugar a problem for the liver?
High blood sugar is identified as the leading driver of MASLD-related health problems, contributing to the accumulation of fat in the liver and subsequent inflammation.

What happens if MASLD is left untreated?
If it progresses to more aggressive forms like MASH, it can lead to end-stage liver disease and may eventually require a liver transplant.